 Andrew Novick
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress, Psychological | 9 | 2023 | 1133 | 1.480 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2022 | 185 | 1.300 |
Why?
| | Social Behavior | 4 | 2016 | 293 | 1.100 |
Why?
| | Neurosciences | 2 | 2024 | 25 | 1.070 |
Why?
| | Psychiatry | 4 | 2024 | 188 | 1.020 |
Why?
| | Object Attachment | 2 | 2019 | 48 | 0.890 |
Why?
| | Perimenopause | 1 | 2023 | 66 | 0.780 |
Why?
| | Reward | 4 | 2024 | 256 | 0.760 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2021 | 34 | 0.700 |
Why?
| | Prefrontal Cortex | 5 | 2015 | 316 | 0.680 |
Why?
| | Estrogen Antagonists | 1 | 2020 | 45 | 0.660 |
Why?
| | Tobacco Use Disorder | 1 | 2022 | 245 | 0.660 |
Why?
| | Midwifery | 1 | 2021 | 61 | 0.650 |
Why?
| | Menopause | 1 | 2023 | 320 | 0.650 |
Why?
| | Dominance-Subordination | 3 | 2015 | 16 | 0.640 |
Why?
| | Dopamine | 5 | 2015 | 309 | 0.620 |
Why?
| | Tamoxifen | 1 | 2020 | 203 | 0.620 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 170 | 0.610 |
Why?
| | Asphyxia | 1 | 2019 | 20 | 0.600 |
Why?
| | Panic Disorder | 1 | 2019 | 23 | 0.590 |
Why?
| | Cognition | 4 | 2023 | 1228 | 0.590 |
Why?
| | Receptors, Opioid, mu | 1 | 2019 | 70 | 0.580 |
Why?
| | Smoking Cessation | 1 | 2022 | 440 | 0.580 |
Why?
| | Mental Disorders | 3 | 2024 | 1130 | 0.570 |
Why?
| | Citalopram | 1 | 2018 | 35 | 0.570 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 50 | 0.570 |
Why?
| | Anhedonia | 1 | 2018 | 16 | 0.560 |
Why?
| | Affect | 1 | 2020 | 316 | 0.550 |
Why?
| | Pregnancy Complications | 1 | 2022 | 587 | 0.520 |
Why?
| | Sleep | 1 | 2024 | 885 | 0.510 |
Why?
| | Depression | 3 | 2023 | 1508 | 0.500 |
Why?
| | CA3 Region, Hippocampal | 1 | 2016 | 7 | 0.490 |
Why?
| | Mental Health | 1 | 2022 | 759 | 0.470 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 663 | 0.470 |
Why?
| | Pandemics | 1 | 2024 | 1656 | 0.460 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 60 | 0.450 |
Why?
| | Social Dominance | 2 | 2011 | 19 | 0.440 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 228 | 0.420 |
Why?
| | Space Perception | 1 | 2013 | 86 | 0.390 |
Why?
| | Libido | 2 | 2023 | 25 | 0.380 |
Why?
| | Fear | 1 | 2016 | 347 | 0.380 |
Why?
| | Technology | 2 | 2024 | 94 | 0.380 |
Why?
| | Receptors, Dopamine D1 | 2 | 2011 | 34 | 0.370 |
Why?
| | Smokers | 2 | 2022 | 144 | 0.360 |
Why?
| | Memory, Short-Term | 1 | 2013 | 267 | 0.340 |
Why?
| | Progesterone | 2 | 2022 | 263 | 0.340 |
Why?
| | Antidepressive Agents | 2 | 2024 | 254 | 0.340 |
Why?
| | Humans | 24 | 2024 | 141754 | 0.320 |
Why?
| | Cross-Over Studies | 2 | 2022 | 582 | 0.320 |
Why?
| | Nicotine | 2 | 2022 | 350 | 0.310 |
Why?
| | Safety | 1 | 2011 | 356 | 0.290 |
Why?
| | Animals | 12 | 2024 | 37749 | 0.250 |
Why?
| | Female | 12 | 2024 | 75943 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 5 | 2015 | 2525 | 0.240 |
Why?
| | Brain | 4 | 2024 | 2868 | 0.220 |
Why?
| | Pregnancy | 3 | 2022 | 7092 | 0.220 |
Why?
| | Rats | 5 | 2016 | 5637 | 0.220 |
Why?
| | Electronics | 1 | 2024 | 72 | 0.210 |
Why?
| | Premenstrual Dysphoric Disorder | 1 | 2023 | 19 | 0.210 |
Why?
| | Allostasis | 1 | 2023 | 18 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 330 | 0.200 |
Why?
| | Pregnanolone | 1 | 2022 | 42 | 0.190 |
Why?
| | Serotonin | 1 | 2024 | 323 | 0.180 |
Why?
| | Antipsychotic Agents | 1 | 2024 | 212 | 0.180 |
Why?
| | Prisoners | 1 | 2024 | 142 | 0.180 |
Why?
| | Postmenopause | 1 | 2023 | 371 | 0.180 |
Why?
| | Neuronal Plasticity | 1 | 2024 | 305 | 0.180 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.170 |
Why?
| | Mood Disorders | 1 | 2022 | 141 | 0.170 |
Why?
| | Taste | 1 | 2023 | 232 | 0.170 |
Why?
| | Piperazines | 2 | 2015 | 373 | 0.170 |
Why?
| | Fatigue | 1 | 2022 | 339 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 539 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2016 | 4421 | 0.160 |
Why?
| | Cues | 1 | 2022 | 324 | 0.160 |
Why?
| | Estradiol | 1 | 2023 | 528 | 0.160 |
Why?
| | Contraception | 1 | 2022 | 166 | 0.160 |
Why?
| | Benzazepines | 2 | 2011 | 35 | 0.160 |
Why?
| | Biomarkers | 1 | 2011 | 4190 | 0.160 |
Why?
| | Schizophrenia | 1 | 2024 | 454 | 0.160 |
Why?
| | Mindfulness | 1 | 2022 | 148 | 0.160 |
Why?
| | Adolescent | 3 | 2023 | 22130 | 0.150 |
Why?
| | Nucleus Accumbens | 2 | 2012 | 151 | 0.150 |
Why?
| | Anxiety Disorders | 1 | 2022 | 380 | 0.150 |
Why?
| | Sexual Behavior | 1 | 2023 | 498 | 0.140 |
Why?
| | Pilot Projects | 1 | 2024 | 1826 | 0.140 |
Why?
| | Fetus | 1 | 2022 | 802 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2017 | 19 | 0.140 |
Why?
| | Health Personnel | 1 | 2024 | 738 | 0.130 |
Why?
| | Freezing Reaction, Cataleptic | 1 | 2016 | 22 | 0.120 |
Why?
| | Tritium | 1 | 2016 | 72 | 0.120 |
Why?
| | Dizocilpine Maleate | 1 | 2016 | 24 | 0.120 |
Why?
| | Mothers | 1 | 2022 | 785 | 0.120 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2016 | 105 | 0.120 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 6 | 0.120 |
Why?
| | Desipramine | 1 | 2015 | 11 | 0.120 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2015 | 18 | 0.120 |
Why?
| | Male | 10 | 2024 | 70179 | 0.120 |
Why?
| | Anxiety | 1 | 2022 | 1090 | 0.110 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2015 | 60 | 0.110 |
Why?
| | Smoking | 1 | 2022 | 1603 | 0.110 |
Why?
| | Mesencephalon | 1 | 2013 | 66 | 0.100 |
Why?
| | Maze Learning | 1 | 2013 | 104 | 0.100 |
Why?
| | Sexual Maturation | 1 | 2013 | 55 | 0.100 |
Why?
| | Receptors, Dopamine D2 | 1 | 2013 | 96 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1321 | 0.100 |
Why?
| | Amphetamine | 1 | 2012 | 37 | 0.100 |
Why?
| | DNA Methylation | 1 | 2017 | 648 | 0.100 |
Why?
| | Child | 3 | 2023 | 22414 | 0.090 |
Why?
| | Locomotion | 1 | 2012 | 107 | 0.090 |
Why?
| | Child Abuse | 1 | 2017 | 547 | 0.090 |
Why?
| | Radioligand Assay | 1 | 2011 | 37 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 3737 | 0.090 |
Why?
| | Limbic System | 1 | 2011 | 52 | 0.090 |
Why?
| | Maternal Deprivation | 1 | 2011 | 16 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2064 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2022 | 6289 | 0.080 |
Why?
| | Bullying | 1 | 2011 | 44 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2242 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 861 | 0.080 |
Why?
| | Age Factors | 2 | 2013 | 3294 | 0.070 |
Why?
| | Young Adult | 2 | 2024 | 13749 | 0.070 |
Why?
| | Rats, Inbred WKY | 1 | 2008 | 36 | 0.070 |
Why?
| | Autoradiography | 1 | 2008 | 69 | 0.070 |
Why?
| | Neostriatum | 1 | 2008 | 36 | 0.070 |
Why?
| | Substantia Nigra | 1 | 2008 | 58 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2011 | 411 | 0.070 |
Why?
| | Rats, Wistar | 1 | 2008 | 455 | 0.060 |
Why?
| | Species Specificity | 1 | 2008 | 583 | 0.060 |
Why?
| | Amygdala | 1 | 2008 | 192 | 0.060 |
Why?
| | Adult | 3 | 2024 | 39391 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2608 | 0.060 |
Why?
| | Emotions | 1 | 2011 | 579 | 0.060 |
Why?
| | Life Cycle Stages | 1 | 2023 | 41 | 0.050 |
Why?
| | Social Isolation | 1 | 2024 | 66 | 0.050 |
Why?
| | Social Justice | 1 | 2024 | 84 | 0.050 |
Why?
| | Connectome | 1 | 2024 | 93 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2023 | 134 | 0.050 |
Why?
| | Pituitary-Adrenal System | 1 | 2023 | 172 | 0.050 |
Why?
| | Neural Pathways | 1 | 2024 | 308 | 0.050 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2023 | 207 | 0.050 |
Why?
| | Food Preferences | 1 | 2023 | 124 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 464 | 0.040 |
Why?
| | Risk | 1 | 2024 | 907 | 0.040 |
Why?
| | Social Class | 1 | 2023 | 268 | 0.040 |
Why?
| | Electroencephalography | 1 | 2023 | 524 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1317 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2017 | 187 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2023 | 2938 | 0.030 |
Why?
| | Child, Preschool | 2 | 2023 | 11512 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2023 | 1123 | 0.030 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2013 | 5 | 0.030 |
Why?
| | Sulpiride | 1 | 2013 | 5 | 0.030 |
Why?
| | Quinpirole | 1 | 2013 | 10 | 0.030 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 2013 | 19 | 0.030 |
Why?
| | Microdialysis | 1 | 2013 | 54 | 0.030 |
Why?
| | Dopamine Agonists | 1 | 2013 | 43 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 2013 | 90 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1243 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1866 | 0.020 |
Why?
| | Obesity | 1 | 2024 | 3008 | 0.020 |
Why?
| | Signal Transduction | 1 | 2017 | 5169 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 34647 | 0.010 |
Why?
|
|
Novick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|